Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Newron Enters New Year With High Hopes For Evenamide

Jan 02 2024

• By Kevin Grogan

Schizophrenia — • Source: Shutterstock

Related Content

BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy

Dec 22 2023

Newron Points ‘Future Value-Driver’ Evenamide At Drug-Resistant Schizophrenia

Feb 16 2023

Related Companies

Zambon Company S.p.A.

Meiji Seika Pharma Co., Ltd

Supernus Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Karuna Therapeutics, Inc.

Additional Topics

Clinical Trials Strategy Drug Review Research & Development Neurology BioPharmaceutical

More from Neurological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window